EURO MEDLAB 2013 Best Poster Award

27th May

TATAA SPIDIA collaborator Francesca Malentacchi awarded best poster at EURO MEDLAB 2013 for the SPIDIA RNA quality proficiency ring trial

» Poster Euro Medlab 2013

» M. Pazzagli, F. Malentacchi, L. Simi, C. Orlando, R. Wyrich, K. Günther, C.C. Hartmann,P. Verderio, S. Pizzamiglio, C.M. Ciniselli, A. Tichopad, M. Kubista, S. Gelmini. SPIDIA-RNA: First external quality assessment for the pre-analytical phase of blood samples used for RNA based analyses. Methods 59, 20-31 (2013)

» Read about TATAA’s Quality Control qPCR Products

The role of astrocytes in stroke, brain plasticity and neurogenesis

21st May

TATAA collaborator Daniel Andersson defends his PhD thesis “The role of astrocytes in stroke, brain plasticity and neurogenesis” at Gothenburg University on May 30

» Read more

Much of the experimental work has been done at TATAA core facility

» Read about TATAA Core Facility

Market reports available!

21st May

”qPCR and NGS” and “Mass spectrometry for clinical diagnostics” 2013 market reports now available

» Read about the qPCR and NGS market report

» Read about the Mass Spectrometry for Clinical Diagnostics Market Report

Pressrelease

20th May

TATAA Biocenter Expands Offerings using AATI’s Fragment Analyzer™ to assess RNA quality in gene expression analysis

TATAA Biocenter, Europe´s leading provider of genomic services, is strengthening its quality assurance program by introducing RNA quality assessment using Advanced Analytical Technologies, Inc. (“AATI”) Fragment Analyzer™ into its company’s Standard Operating Procedures (SOPs) for expression profiling. “As we are analysing more and more complex samples, including preserved materials such as formalin fixed and paraffin embedded tissues, soils and sewer samples, and other aggressive matrices, the quality of the extracted nucleic acids becomes critical for meaningful analysis. Much money can be saved by identifying problems at an early stage and either discarding poor quality samples or replacing them. With the Fragment Analyzer™ we can do this in high throughput, at acceptable cost and with greatest confidence”, says Dr. Mikael Kubista, founder and CEO of TATAA Biocenter.

Since the Fragment Analyzer™ product launch in early 2012, AATI has placed over 275 units worldwide and has quickly become the technology solution standard to which all others are measured within the rapidly expanding nucleic acids analysis industry.

“We couldn’t be more pleased to have an organization with the creditability of TATAA Biocenter added to our customer list. The Fragment Analyzer™ was designed and built with end-users first in mind,” said Dr. Steven Lasky, founder and CEO of AATI. “When we speak with potential users of the Fragment Analyzer™ we hear the same problem, they are frustrated with the existing competitive solutions; lack of ability to scale with their throughput, lack of reproducible resolution and lack of ability to perform multiple assessments on a single machine. Our proprietary technology allows us to streamline sample processing steps, analyze PCR and NGS library DNA fragments, total and messenger RNA, genomic DNA and DNA mutation detection assays all under one foot print. Together these attributes facilitate an enhanced return on capital for our customers.”

About Advanced Analytical Technologies, Inc.

AATI provides innovative solutions to improve processes and accelerate research results through quality data output within the pharmaceutical, life science, biofuels and biotechnology markets. AATI’s product portfolio includes instruments for the parallel analysis of biomolecules, nucleic acids and proteins by capillary electrophoresis as well as a full line of certified reagents and off the shelf kits to meet customer needs. Founded in 1997, AATI has facilities in Ames, Iowa, USA and Heidelberg, Germany as well as a network of highly qualified distributors throughout the world. For more information visit the company’s website at http://www.aati-us.com or contact us at info@aati-us.com

About TATAA Biocenter

TATAA Biocenter is the world’s largest organizer of hands-on training in quantitative real-time PCR, Europe’s leading provider of nucleic acid analysis services and Sweden’s most comprehensive distributor of products for nucleic acids analysis. TATAA Biocenter has the best equipped laboratories for qPCR based analysis in Europe, and provides a full range of nucleic acid analysis services, including primer and probe design, assay validation, quality control, mRNA and protein expression profiling, SNP and rare mutation analyses, data mining, pathway analysis and kit and instrument evaluation to pharmaceutical and biotech companies. TATAA offers a seamless workflow, with all the instrumentation necessary for performing high quality experiments and for optimal sample handling, meeting the specific requirements for compliance with ISO17025 standard. TATAA core facility laboratories are also available for academic researchers. Founded in 2001, TATAA has permanent facilities in Gothenburg, Sweden, and Prague, Czech Republic.

For more information about TATAA Biocenter, see www.tataa.com or contact us on info@tataa.com

 

Single Cell Expression Profiling

16th May

Video presentation ”Single Cell Expression Profiling” by Mikael Kubista, TATAA Biocenter

» Watch Video

» Info on TATAA Cellulyser for single cell extraction

TATAA Biocenter installs the Fragment Analyzer

15th May

TATAA Biocenter installs the Fragment Analyzer from Advanced Analytical for RNA quality assessment and DNA library qualification

» Read about the Fragment Analyzer and Advanced Analytical

» Read the article in GEN on “Simplifying HT RNA Quality & Quantity Analysis”

» Find out more about TATAA service offerings in RNA analysis and quality assessment

microRNA Analysis Guide

14th May

Guide for microRNA expression analysis by Exiqon

» Read the Guide

» Read about TATAA microRNA profiling services

» Info about qPCR data analysis softwares

Protein profiling service offer

6th May

Next Generation High-Throughput Protein Profiling

We provide next generation high-throughput protein profiling with the proximity extension assay (PEA) technology, developed by Olink Bioscience. For the first time it is possible to do high capacity quantification of 92 cancer-related protein biomarkers in 96 samples in a single run.

With only 1 µl sample consumption this method is especially suitable for biomarker studies in precious samples from serum, plasma, tissue etc.

Services

  • Protein expression and pathway analysis using Proseek® Multiplex Oncology I 96×96
    • High-throughput quantification of 92 cancer-related protein biomarkers in 96 samples simultaneously, generating 9,216 data points
    • Data analysis

TATAA Offer – Protein Profiling

Only 75 EUR per sample!

 

 

Image is © Olink AB
and used with permission

 

Welcome to a new world of scalable immunoassays

Biomarker studies which were previously limited by poor assay sensitivity, low throughput systems and insufficient sample amount are now feasible in a simple and efficient way.

Conventional immunoassays have been unable to scale due to increasing antibody cross-reactivity but TATAA Biocenter offers a truly scalable method that generates high quality data even in highly multiplexed formats and the opportunities are enormous for powerful analysis of multivariate biomarker patterns.

The quantification is performed using the Fluidigm BioMark™ HD Real-time PCR Platform and generates 9,216 data points in a single run.

  • Discover novel expression patterns of 92 protein biomarkers in precious biological materials
  • Growth factors, inflammatory markers, soluble receptors etc.
  • Go from single to multiplex without compromising the analytical performance

Contact and more information

To learn more about our Protein Profiling Service and the biomarkers included in Proseek® Multiplex Oncology I 96×96, please visit our website

For further questions about our services, please contact services@tataa.com


♦Price offer only for Academics when analyzing 92 samples simultaneously. The price offer is valid for order confirmations until 1 July 2013 and if projects are analysed until October 31. For smaller batch sizes there might be a waiting period. Basic data analysis is included.

Proseek is a trademark of Olink AB. Proseek® Multiplex is for research use only. Not for use in human diagnostics or therapeutic procedures. Proseek® Multiplex is sold under license from PHRI Properties, Inc., and may be used under the PHRI Properties patent rights outside the field of human in vitro diagnostics.

TATAA course in Boston

6th May

Join TATAA course in Boston May 7-8 on Biostatistics at Genomics Research 2013 meeting by Select Biosciences

» Read about the course

» Information about TATAA courses

”MIQE qPCR Guidelines, Three Years Later”

3rd May

» Read the Article

» Read about TATAA qPCR QC Tools